News

Biotechs snap up EU money
Enlarge image

FundingBelgiumGermanyIrelandNetherlandsUK

Biotechs snap up EU money

16.04.2013 - Biotechs involved in the bio-economy initiatives of five European countries pool their expertise in an EU project termed BioBaseNWE.

The partners from Bio Base Europe international non-profit organisation (BE), Ghent Bio-Energy Valley (BE), Bio Base Europe Training Center (NL), REWIN/Biobased Innovations (NL), German Cluster Industrielle Biotechnologie, Galway-based Competence Centre for Biorefining and Bioenergy (IRL) and the British National Non-Food Crops Centre (UK) have secured €6.2m from the European Commission.

The overall goal of the Bio Base NWE project is to drive growth and education in the bio-based economy in north-western Europe. The project gets 50% of its €12m overall budget through the INTERREG IVB North West Europe Programme, the other 50% from Agentschap Ondernemen (BE), Biobased delta (NL), Provincie Noord-Brabant (NL), Provincie Zeeland (NL), National University of Ireland NUI Galway, Industrial Development Agency (IDA) Ireland, Enterprise Ireland, and the National Development Plan Ireland. “Bio-based products are a growing area of interest for SMEs working in the chemical industry, agro-industry, plastics, fuels, food, textile and pharma industry“ stressed project manager Lieve Hoflack. „However, many SME’s find it difficult to bridge the gap between newly developed research and the commercial market,” she added.

The network will advise SMEs on how to get financial support for projects at a pilot plant in Ghent. This flexible pilot plant will selectively invest in equipment for promising technologies to promote further growth. The partnership will also develop and deliver programmes and tools for training skilled professionals for bio-based industries.

© eurobiotechnews.eu/tg

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK8.53%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.46 EUR-10.26%

TOP

  • WILEX (D)2.82 EUR231.8%
  • ADDEX (CH)3.80 CHF58.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK44.9%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.67 USD-23.8%
  • VITA 34 (D)4.18 EUR-20.4%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)431.00 GBP676.6%
  • PAION (D)2.42 EUR255.9%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.6%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-70.4%

No liability assumed, Date: 30.07.2014